Strategic partnerships There are active collaborations with academic and medical centers (CHUV) and industry partners (Admera Health) indicating openness to joint research initiatives and service-based engagements that could expand consulting, service, or integrated workflow offerings.

Legal and IP traction Recent patent infringement litigation outcomes against competitors suggest a competitive edge in proprietary technologies and potential upsell of validated Xenium and single-cell solutions to customers concerned about patent clearance and vendor reliability.

Revenue growth signals Q2 2026 revenue of 151 million, while down from the prior year, still positions 10x Genomics as a high-value supplier in single-cell and spatial technologies with opportunities to win back growth through expanded product bundles and service contracts.

Expansion opportunities Active product focus on Xenium spatial biology and collaborations for cancer diagnostics indicate cross-sell potential to oncology, immunology, and pathology segments, alongside offering turnkey genomic workflows for labs scaling up single-cell analyses.

Operational footprint A sizeable enterprise with a broad tech stack and multiple customer-facing platforms suggests the need for enterprise-grade procurement, service SLAs, and ecosystem integrations, presenting opportunity to offer managed services, training, and systems integration packages.